• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Veracyte, Inc. - Common Stock (NQ:VCYT)

    32.85 +1.07 (+3.37%)
    Streaming Delayed Price Updated: 3:48 PM EDT, Apr 30, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 398,015
    Open 31.90
    Bid (Size) 32.82 (200)
    Ask (Size) 32.86 (100)
    Prev. Close 31.78
    Today's Range 31.57 - 33.08
    52wk Range 22.61 - 50.71
    Shares Outstanding 67,473,870
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Veracyte Inc (NASDAQ:VCYT): A High-Growth Biotech Stock Poised for a Technical Breakout ↗
    Via Chartmill
    News headline image
    Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers
    From Veracyte, Inc.
    Via Business Wire

    Performance

    YTD
    -22.5%
    -22.5%
    1 Month
    +7.9%
    +7.9%
    3 Month
    -14.6%
    -14.6%
    6 Month
    -7.2%
    -7.2%
    1 Year
    +4.7%
    +4.7%

    More News

    Read More
    Curious about the stocks that are showing activity after the closing bell on Thursday? ↗
    Via Chartmill
    Veracyte Inc (NASDAQ:VCYT) Emerges as a Prime Growth at a Reasonable Price (GARP) Candidate ↗
    Via Chartmill
    Veracyte Inc (NASDAQ:VCYT) Posts Strong Q4 Earnings Beat and Positive 2026 Outlook ↗
    Via Chartmill
    Topics Earnings
    Veracyte Inc (NASDAQ:VCYT): A Prime GARP Stock with Strong Growth and a Sound Balance Sheet ↗
    Via Chartmill
    Veracyte Inc. (NASDAQ:VCYT) Emerges as a Prime Affordable Growth Candidate ↗
    Via Chartmill
    News headline image
    Earnings Scheduled For November 4, 2025 ↗
    Via Benzinga
    News headline image
    Veracyte Names Kevin Haas as Chief Development and Technology Officer
    From Veracyte, Inc.
    Via Business Wire
    News headline image
    Veracyte (VCYT) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results
    From Veracyte, Inc.
    Via Business Wire
    News headline image
    Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium
    From Veracyte
    Via Business Wire
    News headline image
    Veracyte to Participate in Upcoming Investor Conferences
    From Veracyte, Inc.
    Via Business Wire
    News headline image
    Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
    From Veracyte, Inc.
    Via Business Wire
    News headline image
    Biodesix Shares Rocket 42% on Record FY2025 Results and Path to Profitability
    Via MarketMinute
    Topics Artificial Intelligence Death
    News headline image
    Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results
    From Veracyte, Inc.
    Via Business Wire
    News headline image
    Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference
    From Veracyte, Inc.
    Via Business Wire
    News headline image
    Veracyte Inc (NASDAQ:VCYT) Emerges as a Top Affordable Growth Stock ↗
    Via Chartmill
    News headline image
    Veracyte Inc (NASDAQ:VCYT): A GARP Stock With Strong Growth and a Reasonable Price ↗
    Via Chartmill
    News headline image
    Veracyte to Participate in Upcoming Investor Conferences
    From Veracyte, Inc.
    Via Business Wire
    News headline image
    Johnson Controls, Babcock & Wilcox, Lemonade, Lumentum, Teva Pharmaceutical And Other Big Stocks Moving Higher On Wednesday ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Veracyte Announces Third Quarter 2025 Financial Results
    From Veracyte, Inc.
    Via Business Wire
    News headline image
    Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing
    From Veracyte, Inc.
    Via Business Wire
    News headline image
    Veracyte Inc (NASDAQ:VCYT): An Affordable Growth Candidate in Biotech ↗
    Via Chartmill

    Frequently Asked Questions

    Is Veracyte, Inc. - Common Stock publicly traded?
    Yes, Veracyte, Inc. - Common Stock is publicly traded.
    What exchange does Veracyte, Inc. - Common Stock trade on?
    Veracyte, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Veracyte, Inc. - Common Stock?
    The ticker symbol for Veracyte, Inc. - Common Stock is VCYT on the Nasdaq Stock Market
    What is the current price of Veracyte, Inc. - Common Stock?
    The current price of Veracyte, Inc. - Common Stock is 32.85
    When was Veracyte, Inc. - Common Stock last traded?
    The last trade of Veracyte, Inc. - Common Stock was at 04/30/26 03:48 PM ET
    What is the market capitalization of Veracyte, Inc. - Common Stock?
    The market capitalization of Veracyte, Inc. - Common Stock is 2.22B
    How many shares of Veracyte, Inc. - Common Stock are outstanding?
    Veracyte, Inc. - Common Stock has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.